Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 1
Submit an article Journal homepage
288
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation

William ShomaliDepartment of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA
,
Cheryl RedmondDepartment of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
,
Samjhana BogatiDepartment of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
,
Cassandra ZimmermanDepartment of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
,
Valeria VisconteDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
,
Ali TabarrokiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
,
Matt KalaycioDepartment of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
&
Ramon V. TiuDepartment of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA;Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USACorrespondence[email protected]
 show all
Pages 193-195 | Received 16 Oct 2014, Accepted 27 Mar 2015, Published online: 18 Jun 2015

References

  • Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290–293.
  • Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824–830.
  • O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan- BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401–412.
  • Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783–1796.
  • Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367:2075–2088.
  • US Food and Drug Administration (FDA) (Internet). FDA Drug Safety Communication. 2013. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm373040.htm, accessed July 28, 2014.
  • Kantarjian HM, Kim D-W, Pinilla-Ibarz J, et al. Ponatinib in patients with Philadelphia chromosome-positive leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial [abstract]. J Clin Oncol 2014;32(Suppl. 5):Abstract 7081.
  • Talpaz M, Cortes JE, Kantarjian HM, et al. Longer-term follow up of a phase 1 study of ponatinib in patients with Philadelphia chromosome-positive leukemias [abstract]. J Clin Oncol 2014;32(Suppl. 5): Abstract 7078.
  • Nicolini F, Gagnieu M-C, Heiblig M, et al. Cardio-vascular events occurring on ponatinib in chronic phase chronic myeloid leukemia patients, preliminary analysis of a multicenter cohort [abstract]. Blood 2013;122:4020.
  • Le Coutre P, Hughes TP, Mahon F-X, et al. Peripheral arterial occlusive disease in patients receiving dasatinib: experience across multiple clinical trials [abstract]. Blood 2013;122:1489.
  • Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533–539.
  • Canning P, Tan L, Chu K, et al. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors. J Mol Biol 2014;426:2457–2470.
  • Hochhaus A, Pinilla-Ibarz J, Kim D-W, et al. Clinical impact of dose modification and dose intensity on response to ponatinib in patients with Philadelphia chromosome-positive leukemias [abstract]. J Clin Oncol 2014;32(Suppl. 5):Abstract 7084.
  • Cortes J, Borthakur G, Pemmaraju N, et al. Ponatinib as initial therapy for patients with chronic myeloid leukemia in chronic phase [abstract]. Blood 2013;122:1483.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.